Form D · Biotechnology
Jounce Therapeutics, Inc.
Cambridge, MA · CIK 0001640455
Offering snapshot reported Oct 29, 2020 · SEC filing
- Reported sold
- $35M Offering amount: $35M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 16, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2020 | Initial | $34,999,995 | No comparison | 1 | SEC filing |
| Apr 29, 2015 | Initial | $56,000,000 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-379231
Source: Form D, filed Oct 29, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anna L. Barry | Executive |
| Hugh M. Cole | Executive |
| Luis A. Diaz, Jr. | Director |
| Kimberlee C. Drapkin | Executive |
| Kim C. Drapkin | Executive |
| Barbara Duncan | Director |
| Duncan Higgons | Director |
| Robert Iannone | Director |
| Robert Kamen | Director |
| Perry Karsen | Director |
| Richard Murray | Director, Executive |
| Cary Pfeffer | Director |
| Robert Tepper | Director |
| Elizabeth G. Trehu | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
780 Memorial Drive
Cambridge, MA, 02139
Cambridge, MA, 02139